Type 2 diabetes: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

  NCT07668336· Eli Lilly and Company· Source

• Evaluating the Effectiveness of a Multi-level Health-Related Social Needs Initiative

  NCT06831162· Vanderbilt University Medical Center· Source

• UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

  NCT07163624· The United Bio-Technology (Hengqin) Co., Ltd.· Source

• A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

  NCT07670416· Hoffmann-La Roche· Source

• Linking Education, Produce Provision, and Community Referrals to Improve Diabetes Care (LINK)

  NCT05472441· Ohio State University· Source

• A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

  NCT07595549· Pfizer· Source

• Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes

  NCT07866066· Amgen· Source

• Community Health Worker Nutrition Self-Management Support for Cardio-Kidney-Metabolic Health

  NCT07918508· Florida International University· Source

• A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)

  NCT07915609· Pfizer· Source

• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

  NCT06897475· Eli Lilly and Company· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 25
• Organoids 3
• Mendelian Randomization Analysis 227
• CRISPR-Cas Systems 5
• Gene Expression Profiling 111
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 8
• Exome Sequencing 12
• Proteomics 147
• Metabolomics 201
• Mass Spectrometry 42
• Flow Cytometry 19
• Immunohistochemistry 50
• Xenograft Model Antitumor Assays 34
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 184
• Machine Learning 190
• Deep Learning 32
• Cohort Studies 1106
• Genome-Wide Association Study 313

• Identification of ageing-related genes in prostate cancer with type 2 Diabetes using machine learning: a multi-omics study focusing on SOX4, PRNP, and FOXO4.

  Artif Cells Nanomed Biotechnol, Oct 2026

• Dissecting polycystic metabolic ovarian syndrome heterogeneity (PMOS): multi-omics, AI subtyping, and precision management.

  Mol Biol Rep, Oct 2026

• [Construction of predictive models for type 2 diabetic retinopathy based on the principle of differentiation of syndrome elements].

  Nan Fang Yi Ke Da Xue Xue Bao, Oct 2026

• Machine learning predictors of cardiovascular autonomic neuropathy in type 2 diabetes: insights from a prospectively collected single-center registry.

  Front Endocrinol (Lausanne), Oct 2026

• Integrative Bioinformatics Analysis Incorporating Artificial Intelligence and Machine Learning Identifies Putative Pathogenic HNF1B Missense Variants Associated with HNF1B-MODY.

  Int J Mol Sci, Oct 2026

• A machine learning-driven and explainable prediction model for in-hospital mortality in patients with diabetes mellitus and congestive heart failure: integrating XGBoost and SHAP approaches.

  Front Public Health, Oct 2026

• Interpretable machine learning models to predict venous thromboembolism in sepsis patients with type 2 diabetes mellitus.

  Front Endocrinol (Lausanne), Sept 2026

• Chemometrics-assisted FTIR and machine learning for biochemical profiling of human skeletal muscles in relation to type 2 diabetes.

  Spectrochim Acta A Mol Biomol Spectrosc, Sept 2026

• Integrative bioinformatics and machine learning reveal hub genes and immune signatures bridging type 2 diabetes mellitus, fracture susceptibility, and osteoblast differentiation dysfunction.

  Mamm Genome, Sept 2026

• Development and Validation of a Machine Learning-Based Model for Predicting All-Cause Mortality Risk in Patients With Type 2 Diabetes Mellitus Combined With Hypertension: National Cohort Study.

  JMIR Med Inform, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.